At the time of writing, Larimar Therapeutics Inc [LRMR] stock is trading at $2.30, up 15.58%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The LRMR shares have gain 19.17% over the last week, with a monthly amount drifted -3.77%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Larimar Therapeutics Inc [NASDAQ: LRMR] stock has seen the most recent analyst activity on January 29, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $18. Previously, Oppenheimer started tracking the stock with Outperform rating on October 16, 2024, and set its price target to $26. On October 03, 2024, Wedbush initiated with a Outperform rating and assigned a price target of $22 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $15 on October 02, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $16 as its price target on September 04, 2024. Leerink Partners started tracking with a Outperform rating for this stock on April 03, 2024, and assigned it a price target of $25. In a note dated November 17, 2023, Citigroup upgraded an Buy rating on this stock but restated the target price of $4.50.
For the past year, the stock price of Larimar Therapeutics Inc fluctuated between $1.61 and $11.20. Currently, Wall Street analysts expect the stock to reach $15 within the next 12 months. Larimar Therapeutics Inc [NASDAQ: LRMR] shares were valued at $2.30 at the most recent close of the market. An investor can expect a potential return of 552.17% based on the average LRMR price forecast.
Analyzing the LRMR fundamentals
Gross Profit Margin for this corporation currently stands at 0.33% with Operating Profit Margin at -437.11%, Pretax Profit Margin comes in at -395.15%, and Net Profit Margin reading is -395.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -0.52 and Total Capital is -0.71. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.0600 points at the first support level, and at 1.8300 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.4300, and for the 2nd resistance point, it is at 2.5700.
Ratios To Look Out For
It is important to note that Larimar Therapeutics Inc [NASDAQ:LRMR] has a current ratio of 7.48. Further, the Quick Ratio stands at 7.48, while the Cash Ratio is 0.95.
